Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
Altimmune (NASDAQ:ALT) has appointed Linda M. Richardson as Chief Commercial Officer, effective September 16, 2025. Richardson brings over 30 years of experience in sales, marketing, and commercial development, with expertise in metabolic disease, hepatology, cardiovascular, and addiction medicine.
Richardson joins Altimmune as the company approaches Phase 3 development of pemvidutide in MASH. She previously served as Chief Commercial Officer at Intercept Pharmaceuticals until early 2024 and held senior positions at Chimerix, Sanofi, Reliant Pharmaceuticals, and GSK.
As part of her compensation package, Richardson will receive options to purchase 278,000 shares and 96,000 restricted stock units (RSUs), with a four-year vesting schedule.
Altimmune (NASDAQ:ALT) ha nominato Linda M. Richardson come Chief Commercial Officer, con effetto dal 16 settembre 2025. Richardson porta oltre 30 anni di esperienza nelle vendite, nel marketing e nello sviluppo commerciale, con competenze in malattie metaboliche, epatologia, cardiovascolare e medicina delle dipendenze.
Richardson si unisce ad Altimmune mentre l’azienda si avvicina alla fase 3 dello sviluppo di pemvidutide nel programma MASH. In passato è stata Chief Commercial Officer presso Intercept Pharmaceuticals fino all’inizio del 2024 e ha ricoperto ruoli senior presso Chimerix, Sanofi, Reliant Pharmaceuticals e GSK.
Come parte del pacchetto di compensazione, Richardson riceverà opzioni per l’acquisto di 278.000 azioni e 96.000 unità azionarie vincolate (RSU), con un piano di vesting ventiquattro mesi.
Altimmune (NASDAQ:ALT) ha nombrado a Linda M. Richardson como Chief Commercial Officer, con efecto a partir del 16 de septiembre de 2025. Richardson aporta más de 30 años de experiencia en ventas, marketing y desarrollo comercial, con expertise en enfermedades metabólicas, hepatología, cardiovascular y medicina de adicciones.
Richardson se une a Altimmune a medida que la compañía se aproxima a la fase 3 del desarrollo de pemvidutide en MASH. Anteriormente se desempeñó como Chief Commercial Officer en Intercept Pharmaceuticals hasta principios de 2024 y ocupó puestos en Chimerix, Sanofi, Reliant Pharmaceuticals y GSK.
Como parte de su paquete de compensación, Richardson recibirá opciones para comprar 278.000 acciones y 96.000 unidades de acciones restringidas (RSU), con un calendario de vesting de cuatro años.
Altimmune(NASDAQ:ALT)는 Linda M. Richardson를 최고상업책임자(CCO)로 임명했으며, 유효 시기는 2025년 9월 16일입니다. Richardson은 매출, 마케팅 및 상업 개발 분야에서 30년 이상의 경험을 보유하고 있으며 대사질환, 간질환, 심혈관계 및 중독의학에 전문성을 갖추고 있습니다.
Richardson은 Pemvidutide의 MASH 프로그램에서 3상 개발에 접근함에 따라 Altimmune에 합류합니다. 이전에는 Intercept Pharmaceuticals에서 2024년 초까지 최고상업책임자를 역임했고 Chimerix, Sanofi, Reliant Pharmaceuticals, GSK에서 고위직을 맡았습니다.
보상 패키지의 일부로 Richardson은 278,000주의 주식매수선택권과 96,000주의 RSU를 받게 되며, 4년 vesting 일정으로 부여됩니다.
Altimmune (NASDAQ:ALT) a nommé Linda M. Richardson au poste de Chief Commercial Officer, à compter du 16 septembre 2025. Richardson apporte plus de 30 années d’expérience dans les ventes, le marketing et le développement commercial, avec une expertise en maladies métaboliques, hépatologie, cardiovasculaire et médecine des addictions.
Elle rejoint Altimmune alors que l’entreprise s’approche du développement de pemvidutide en phase 3 dans le cadre du programme MASH. Elle occupait auparavant le poste de Chief Commercial Officer chez Intercept Pharmaceuticals jusqu’au début de 2024 et a occupé des postes senior chez Chimerix, Sanofi, Reliant Pharmaceuticals et GSK.
Dans le cadre de son package de rémunération, Richardson recevra des options d’achat pour 278 000 actions et 96 000 unités d’actions restreintes (RSU), avec un calendrier de vesting sur quatre ans.
Altimmune (NASDAQ:ALT) hat Linda M. Richardson zur Chief Commercial Officer ernannt, mit Wirkung zum 16. September 2025. Richardson verfügt über > 30 Jahre Erfahrung in Vertrieb, Marketing und kommerzieller Entwicklung, mit Fachkenntnissen in metabolischen Erkrankungen, Hepatologie, Herz-Kreislauf und Suchtmedizin.
Richardson tritt bei Altimmune ein, da das Unternehmen sich der Phase-3-Entwicklung von Pemvidutide im MASH-Programm nähert. Zuvor war sie Chief Commercial Officer bei Intercept Pharmaceuticals bis Anfang 2024 und bekleidete leitende Positionen bei Chimerix, Sanofi, Reliant Pharmaceuticals und GSK.
Im Rahmen ihres Vergütungspakets erhält Richardson Optionen zum Kauf von 278.000 Aktien und 96.000 Restricted Stock Units (RSU) mit einem Vier-Jahres-Vesting-Plan.
عينت Altimmune (المدرجة في ناسداك: ALT) ليندا م. ريتشاردسون في منصب كبير المسؤولين التجاريين، على أن يكون ذلك نافذاً اعتباراً من 16 سبتمبر 2025. تمتلك ريتشاردسون أكثر من 30 عاماً من الخبرة في المبيعات والتسويق وتطوير الأعمال، مع خبرة في أمراض التمثيل الغذائي وأمراض الكبد والقلب والأوعية الدموية وطب الإدمان.
تنضم ريتشاردسون إلى Altimmune مع اقتراب الشركة من تطوير المرحلة الثالثة من pemvidutide في برنامج MASH. شغلت سابقاً منصب كبير المسؤولين التجاريين في Intercept Pharmaceuticals حتى أوائل 2024 وتولّت مناصب عليا في Chimerix وSanofi وReliant Pharmaceuticals وGSK.
كجزء من حزمة التعويضات، ستتلقى ريتشاردسون خيار شراء 278,000 سهم و 96,000 وحدة أسهم مقيدة (RSU)، مع مخطط vesting لمدة أربع سنوات.
Altimmune（纳斯达克股票代码：ALT） 已任命 Linda M. Richardson 为首席商业官，自2025年9月16日起生效。Richardson 拥有超过 30 年的经验，涵盖销售、市场营销与商业开发，专长于代谢疾病、肝病、心血管疾病与成瘾医学。
她在 Pemvidutide 的 MASH 计划进入三期开发之际加入 Altimmune。此前她曾在 Intercept Pharmaceuticals 担任首席商业官直至 2024 年初，并在 Chimerix、Sanofi、Reliant Pharmaceuticals 以及 GSK 担任高层职位。
作为薪酬方案的一部分，Richardson 将获得 278,000 股的购买股权与 96,000 股受限股票单位（RSU），并设有为期四年的归属计划。
- Strategic hire with extensive commercial experience in relevant therapeutic areas
- Timing aligns with approaching Phase 3 development of pemvidutide
- Richardson's experience includes successful product launches and business development transactions
- Significant equity compensation package may result in dilution for existing shareholders
Insights
Altimmune's CCO hire signals strategic preparation for pemvidutide's commercialization as it approaches pivotal Phase 3 MASH trials.
Altimmune's appointment of Linda Richardson as Chief Commercial Officer represents a strategic milestone in the company's evolution from clinical-stage to commercial-ready organization. With pemvidutide advancing to Phase 3 trials for MASH (Metabolic dysfunction-associated steatohepatitis), this executive addition comes at a critical inflection point. Richardson brings valuable commercial expertise from liver disease leader Intercept Pharmaceuticals, where she served as CCO until its acquisition by Alfasigma in early 2024. Her specific experience with GLP-1 programs at Sanofi and launching Lovaza for hypertriglyceridemia at Reliant Pharmaceuticals is particularly relevant to pemvidutide's mechanism and target indications.
This hire signals management's confidence in pemvidutide's clinical pathway and commercial potential. The company is not only pursuing MASH but also investigating pemvidutide for Alcohol Use Disorder and Alcohol-associated Liver Disease - expanding the potential market opportunity. The substantial equity compensation package (278,000 stock options and 96,000 RSUs with four-year vesting) demonstrates a significant commitment to Richardson and aligns her interests with the company's long-term success. This appointment follows the industry pattern of building commercial infrastructure approximately 12-18 months before potential regulatory submissions, suggesting Altimmune is executing according to standard biotech development timelines for a late-stage asset.
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises and contributed to a variety of business development transactions.
“Linda joining Altimmune marks a key strategic addition to our executive team as we approach the initiation of Phase 3 development of pemvidutide in MASH. To add a leader with her pedigree positions Altimmune, and pemvidutide, for future commercial success,” said Vipin K. Garg, Ph.D., President and CEO of Altimmune. “Her deep expertise and strong track record will be instrumental to our strategic business execution and growth.”
Ms. Richardson added, “I believe that pemvidutide represents a rare opportunity in the area of hepato-metabolic disease and is differentiated from other marketed and development-stage therapies with significant potential to improve the lives of patients with MASH. Additionally, there are sizeable opportunities in Alcohol Use Disorder and Alcohol-associated Liver Disease where we continue to investigate the potential utility of pemvidutide in these highly prevalent and underserved indications. I am pleased to bring my experience to Altimmune and thrilled to begin leading Altimmune’s commercial-readiness efforts.”
Ms. Richardson served as Chief Commercial Officer and Executive Vice President at Intercept Pharmaceuticals, a liver disease company, departing in early 2024 following the Company’s acquisition by Alfasigma. Prior to joining Intercept, she was Chief Strategy and Commercial Officer at Chimerix. Earlier in her career, she held a variety of senior-level marketing and commercial positions, including at Sanofi, where she was Global Commercial Head of Lixisenatide, the Company’s GLP-1 program and Marketing Lead for MULTAQ and AUVI-Q, Reliant Pharmaceuticals, where she launched Lovaza for hypertriglyceridemia, and at GSK. She holds a bachelor’s degree in English from the University of Pennsylvania.
Inducement Grant
In connection with being named as Chief Commercial Officer, Ms. Richardson will receive, in the aggregate, options to purchase 278,000 shares of Altimmune’s common stock, and 96,000 restricted stock units (“RSUs”). The options will have an exercise price equal to the closing price of Altimmune’s common stock on September 16, 2025 (the “Grant Date”). Based on the closing price of Altimmune’s common stock on September 12, 2025, Altimmune would issue approximately 168,112 options as inducement awards under its 2018 Inducement Grant Plan, and the balance as incentive stock options under its 2017 Omnibus Incentive Plan. The final allocation of options between the 2018 Inducement Grant Plan and 2017 Omnibus Plan are subject to adjustment based on the closing price of Altimmune’s common stock on the Grant Date. One-fourth of the shares underlying the options will vest on the one-year anniversary of the Grant Date and thereafter 1/36th of the shares underlying the options will vest monthly, such that the shares underlying the options will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to Ms. Richardson’s continued employment with Altimmune on such vesting dates.
One-fourth of the RSUs will vest on the one-year anniversary of the Grant Date and thereafter the RSUs will vest in three substantially equal annual installments, such that the RSUs will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to Ms. Richardson’s continued employment with Altimmune on such vesting dates. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Forward-Looking Statements
Any statements made in this press release related to the development or commercialization of pemvidutide, an investigational product candidate, and other business, regulatory and financial matters including without limitation, the timing of key milestones for the Company’s clinical assets, future plans or expectations for pemvidutide for the treatment of MASH, AUD, ALD and obesity, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements, or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K, quarterly report on Form 10-Q and the Company’s other filings with the SEC, which are available at www.sec.gov.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
Who is Linda Richardson, the new CCO of Altimmune (NASDAQ:ALT)?
What compensation package will Altimmune's new CCO receive?
What is pemvidutide and why is it important for Altimmune (NASDAQ:ALT)?
When will Linda Richardson start as Altimmune's Chief Commercial Officer?
What are the vesting terms for Richardson's equity compensation at Altimmune?
